Portaels F, Silva MT, Meyers WM, 2009. Buruli ulcer. Clin Dermatol 27: 291–305.
Minime-Lingoupou F, Beyam N, Zandanga G, Manirakiza A, N'Domackrah A, Njuimo S, Eyangoh S, Cottin J, Marsollier L, Marion E, Portaels F, Le Faou A, Bercion R, 2010. Buruli ulcer, Central African Republic. Emerg Infect Dis 16: 746–748.
World Health Organization, 2015. Global Health Observatory Data: Buruli Ulcer. Available at: http://www.who.int/gho/neglected_diseases/buruli_ulcer/en/. Accessed March 21, 2015.
Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, Awua-Boateng NY, Ampadu EO, Siegmund V, Schouten JP, Adjei O, Bretzel G, van der Werf TS, 2010. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375: 664–672.
Goto M, Nakanaga K, Aung T, Hamada T, Yamada N, Nomoto M, Kitajima S, Ishii N, Yonezawa S, Saito H, 2006. Nerve damage in Mycobacterium ulcerans-infected mice: probable cause of painlessness in Buruli ulcer. Am J Pathol 168: 805–811.
En J, Goto M, Nakanaga K, Higashi M, Ishii N, Saito H, Yonezawa S, Hamada H, Small PL, 2008. Mycolactone is responsible for the painlessness of Mycobacterium ulcerans infection (Buruli ulcer) in a murine study. Infect Immun 76: 2002–2007.
Alferink M, de Zeeuw J, Sopoh G, Agossadou C, Abass KM, Phillips RO, Loth S, Jutten E, Barogui Y, Stewart R, van der Werf TS, Stienstra Y, Ranchor A, 2015. Pain associated with wound care treatment among Buruli ulcer patients from Ghana and Benin. PLoS One 10: e0119926.
Sarfo FS, Phillips RO, Zhang J, Abass MK, Abotsi J, Amoako YA, Adu-Sarkodie Y, Robinson C, Wansbrough-Jones MH, 2014. Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease. BMC Infect Dis 14: 202.
Barogui Y, Johnson RC, van der Werf TS, Sopoh G, Dossou A, Dijkstra PU, Stienstra Y, 2009. Functional limitations after surgical or antibiotic treatment for Buruli ulcer in Benin. Am J Trop Med Hyg 81: 82–87.
de Zeeuw J, Alferink M, Barogui YT, Sopoh G, Phillips RO, van der Werf TS, Loth S, Molenbuur B, Plantinga M, Ranchor A, Stienstra Y, 2015. Assessment and treatment of pain during treatment of Buruli ulcer. PLoS Negl Trop Dis 9: e0004076.
Sargent C, 1984. Between death and shame: dimensions of pain in Bariba culture. Soc Sci Med 19: 1299–1304.
Sullivan MJ, Thorn B, Haythornthwaite JA, Keefe F, Martin M, Bradley LA, Lefebvre JC, 2001. Theoretical perspectives on the relation between catastrophizing and pain. Clin J Pain 17: 52–64.
Ruscheweyh R, Albers C, Kreusch A, Sommer J, Marziniak M, 2013. The effect of catastrophizing self-statements on pain perception and the nociceptive flexor reflex (RIII reflex). Clin J Pain 29: 725–732.
Gaumond I, Arsenault P, Marchand S, 2002. The role of sex hormones on formalin-induced nociceptive responses. Brain Res 958: 139–145.
Demir Y, 2012. Non-pharmacological therapies in pain management. Racz GB, Noe CE, eds. Pain Management: Current Issues and Opinions. Available at: http://www.intechopen.com/books/pain-management-current-issues-and-opinions/non-pharmacological-therapies-in-pain-management. Accessed March 16, 2016.
Harding R, Powell RA, Kiyange F, Downing J, Mwangi-Powell F, 2010. Provision of pain- and symptom-relieving drugs for HIV/AIDS in sub-Saharan Africa. J Pain Symptom Manage 40: 405–415.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 1544 | 1414 | 41 |
Full Text Views | 296 | 11 | 0 |
PDF Downloads | 86 | 9 | 0 |
Buruli ulcer (BU) is one of the 17 neglected tropical diseases for which the World Health Organization has adopted resolutions to improve treatment. BU was previously described as a relatively painless condition; however, recent research has indicated that some patients experience substantial pain. The objective of this study was to explore patients' experiences of pain and their expectations for its treatment. Semistructured interviews were conducted in a BU-endemic region of Ghana. Interviews were held with former BU patients (N = 20) and community controls (N = 19). Former patients were asked about BU-related pain and their expectations for its treatment. The interviews were conducted in October 2014, and were audiotaped, translated and transcribed into English, and then qualitatively analyzed. Of the 20 former BU patients interviewed, 19 (95%) reported experiencing pain, with patients reporting pain as a consequence of the ulcer and wound management. Some participants expressed pain through crying, whereas others did not openly express pain, sometimes because they feared the repercussions of doing so. Patients wanted to receive pain relief; however, many were unable to name a medication. Nonpharmaceutical options were cited as being an alternative. Many BU patients experience pain; however, former patients and community members alike appear to have a limited knowledge about available pain relief. A low-cost alternative to medication may be the use of nonpharmaceutical means for pain relief. Routine pain assessment may reduce patients' fear and unwillingness to express pain. Awareness of such issues will be valuable when implementing a BU pain relief guideline.
Financial support: This work was supported by the Gratama foundation and the Buruli Ulcer Groningen (BUG) foundation. Ymkje Stienstra received a VENI grant from the Dutch Organization for Scientific Research.
Authors' addresses: Rebecca J. Woolley, Anita Velink, Tjip S. van der Werf, Janine de Zeeuw, and Ymkje Stienstra, Department of Internal Medicine/Infectious Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, E-mails: r.j.woolley@student.rug.nl, a.velink@umcg.nl, t.s.van.der.werf@umcg.nl, j.de.zeeuw@umcg.nl, and y.stienstra@umcg.nl. Richard O. Phillips, Department of Internal Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana, and School of Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana, E-mail: rodamephillips@gmail.com. William A. Thompson and K. Mohammed Abass, Buruli Ulcer Clinic, Agogo Presbyterian Hospital, Agogo, Ghana, E-mails: wnat111@yahoo.com and abass@agogopresbyhospital.org.
Portaels F, Silva MT, Meyers WM, 2009. Buruli ulcer. Clin Dermatol 27: 291–305.
Minime-Lingoupou F, Beyam N, Zandanga G, Manirakiza A, N'Domackrah A, Njuimo S, Eyangoh S, Cottin J, Marsollier L, Marion E, Portaels F, Le Faou A, Bercion R, 2010. Buruli ulcer, Central African Republic. Emerg Infect Dis 16: 746–748.
World Health Organization, 2015. Global Health Observatory Data: Buruli Ulcer. Available at: http://www.who.int/gho/neglected_diseases/buruli_ulcer/en/. Accessed March 21, 2015.
Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, Awua-Boateng NY, Ampadu EO, Siegmund V, Schouten JP, Adjei O, Bretzel G, van der Werf TS, 2010. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375: 664–672.
Goto M, Nakanaga K, Aung T, Hamada T, Yamada N, Nomoto M, Kitajima S, Ishii N, Yonezawa S, Saito H, 2006. Nerve damage in Mycobacterium ulcerans-infected mice: probable cause of painlessness in Buruli ulcer. Am J Pathol 168: 805–811.
En J, Goto M, Nakanaga K, Higashi M, Ishii N, Saito H, Yonezawa S, Hamada H, Small PL, 2008. Mycolactone is responsible for the painlessness of Mycobacterium ulcerans infection (Buruli ulcer) in a murine study. Infect Immun 76: 2002–2007.
Alferink M, de Zeeuw J, Sopoh G, Agossadou C, Abass KM, Phillips RO, Loth S, Jutten E, Barogui Y, Stewart R, van der Werf TS, Stienstra Y, Ranchor A, 2015. Pain associated with wound care treatment among Buruli ulcer patients from Ghana and Benin. PLoS One 10: e0119926.
Sarfo FS, Phillips RO, Zhang J, Abass MK, Abotsi J, Amoako YA, Adu-Sarkodie Y, Robinson C, Wansbrough-Jones MH, 2014. Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease. BMC Infect Dis 14: 202.
Barogui Y, Johnson RC, van der Werf TS, Sopoh G, Dossou A, Dijkstra PU, Stienstra Y, 2009. Functional limitations after surgical or antibiotic treatment for Buruli ulcer in Benin. Am J Trop Med Hyg 81: 82–87.
de Zeeuw J, Alferink M, Barogui YT, Sopoh G, Phillips RO, van der Werf TS, Loth S, Molenbuur B, Plantinga M, Ranchor A, Stienstra Y, 2015. Assessment and treatment of pain during treatment of Buruli ulcer. PLoS Negl Trop Dis 9: e0004076.
Sargent C, 1984. Between death and shame: dimensions of pain in Bariba culture. Soc Sci Med 19: 1299–1304.
Sullivan MJ, Thorn B, Haythornthwaite JA, Keefe F, Martin M, Bradley LA, Lefebvre JC, 2001. Theoretical perspectives on the relation between catastrophizing and pain. Clin J Pain 17: 52–64.
Ruscheweyh R, Albers C, Kreusch A, Sommer J, Marziniak M, 2013. The effect of catastrophizing self-statements on pain perception and the nociceptive flexor reflex (RIII reflex). Clin J Pain 29: 725–732.
Gaumond I, Arsenault P, Marchand S, 2002. The role of sex hormones on formalin-induced nociceptive responses. Brain Res 958: 139–145.
Demir Y, 2012. Non-pharmacological therapies in pain management. Racz GB, Noe CE, eds. Pain Management: Current Issues and Opinions. Available at: http://www.intechopen.com/books/pain-management-current-issues-and-opinions/non-pharmacological-therapies-in-pain-management. Accessed March 16, 2016.
Harding R, Powell RA, Kiyange F, Downing J, Mwangi-Powell F, 2010. Provision of pain- and symptom-relieving drugs for HIV/AIDS in sub-Saharan Africa. J Pain Symptom Manage 40: 405–415.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 1544 | 1414 | 41 |
Full Text Views | 296 | 11 | 0 |
PDF Downloads | 86 | 9 | 0 |